Vaginal Diseases Clinical Trial
Official title:
Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females
Verified date | November 2013 |
Source | Hahnemann University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Numerous studies demonstrate that patients have improved immediate recovery characteristics following desflurane anesthesia compared to other volatile agents, including sevoflurane. There is limited evidence in the literature to suggest that patients undergoing sevoflurane, compared to desflurane anesthesia, may suffer from limitation in function and cognitive ability for an undetermined, but prolonged period of time following surgery. These differences are not explained pharmacokinetically and may be a result of a direct neurotoxic effect of sevoflurane. An unresolved question is the time required for the ability to return to complex tasks, such as driving, following anesthesia. Commonly, patients are advised not to drive or make important decisions for 24 hours following anesthesia, but this is not well-studied and proscribed on an empiric, rather than scientific, basis with very limited data available.This study will better define recovery characteristics and characterize the severity and duration of cognitive impairment following sevoflurane or desflurane anesthesia after brief outpatient urologic surgery in elderly females using tests of cognitive ability coupled with performance on a driving simulator and cognitive task tests to objectively measure not only testing performance, but also cognitive effort in performing these tests.
Status | Completed |
Enrollment | 57 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 60 Years to 85 Years |
Eligibility |
Inclusion Criteria: - > 65 years old, female subjects - Scheduled for brief urologic surgery (Cyctoscopy, Ureteral stent, Laserlithotripsy, Ureteroscopy, Vaginal sling, Bladder injury repair, Rectocele repair and Stone extraction) - Ability to read, write and speak English language - Driving at least one year Exclusion Criteria: - Preexisting neurological impairment in thinking process - Renal insufficiency or failure - Lack of command of English language - Inability to drive - Motion Sickness |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Hahnemann University Hospital | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Hahnemann University Hospital | Baxter Healthcare Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Opening of Eyes | At 30-45 minutes, following discontinuation of volatile anesthetic at the end of surgery | No | |
Secondary | Time to Discharge From PACU | At 30-45 minutes, following discontinuation of volatile anesthetic at the end of surgery and transfer to PACU | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00566982 -
A Clinical Study to Evaluate the Safety of Ospemifene
|
Phase 3 | |
Completed |
NCT01586364 -
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
|
Phase 3 | |
Completed |
NCT01585558 -
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
|
Phase 3 | |
Completed |
NCT03940612 -
Probiotic for Vaginal Candidiasis in Pregnant Women
|
N/A | |
Terminated |
NCT05788991 -
Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis
|
Phase 4 | |
Completed |
NCT00729469 -
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
|
Phase 3 | |
Completed |
NCT00276094 -
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT02534779 -
Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products
|
N/A | |
Completed |
NCT00630539 -
A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women
|
Phase 2 | |
Completed |
NCT04247022 -
Evaluation of Gynecological Acceptability of a Health Care Product
|
N/A |